Amedisys Inc (AMED) Stock Price Today
Key Stats
- $3.32BMarket Cap
- -Volume
- HealthSector
- $100.9952W High
- $83.7852W Low
- 29 DaysTypical Hold Time
- $3.43BEnterprise Value
- -Div Yield
- -Trading Activity
Track Amedisys Inc (AMED) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Amedisys Inc has traded between a low of $83.78 and a high of $100.99, highlighting its annual price range. Buy and sell Amedisys Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Amedisys Inc
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, high acuity care segment , and personal care services. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States, Hospice segment operates many centers designed to provide comfort and support for terminally ill patients, Personal Care Segment provides individuals with assistance in their daily living activities and High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
Most Recent News
AI infrastructure needs more equity as debt risks rise, with $10T capex forecast over 5 years.
Blackstone President Jon Gray highlighted that AI infrastructure development will require increased equity financing due to concentration risks faced by debt investors. Pimco CEO Emmanuel Roman warned that the $10 trillion capital expenditure estimat...
Gold trades below $3,975 as US midterm election and oil prices influence market sentiment.
Gold is trading near $3,926 an ounce, pressured by expectations of a Federal Reserve rate hike and fluctuating oil prices amid US midterm elections. Cheaper oil briefly supported gold by easing inflation fears, but a US strike on Iran raised crude pr...
ARS Pharmaceuticals rated Buy despite slow adoption of intranasal epinephrine spray and financial challenges
ARS Pharmaceuticals is rated Buy as its current stock price undervalues its pipeline potential despite commercial challenges. Its main product, neffy, an intranasal epinephrine spray, faces slow market adoption and insurance issues but holds promise ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.